All
Orca-T Improves cGVHD-Free Survival Across Hematologic Malignancies
Orca-T improved 1-year survival without severe graft-vs-host disease compared with standard transplant in the Precision-T study.
Analyzing AE Data to Guide Selection of Androgen Receptor Inhibitors in mHSPC
Phase 3 Trial of the ArteraAI Prostate Test Begins Enrollment
The first patient has been enrolled in the PROSTATE-IQ trial of ArteraAI, a multimodal artificial intelligence biomarker test.
The Targeted Pulse: Immunotherapy’s Success in Triple-Negative Breast Cancer and Key FDA Actions to Know
This week's Targeted Pulse highlights immunotherapy’s success in triple-negative breast cancer and key FDA actions shaping treatment advancements.
Machine Learning Transforms Multicancer Detection Tests
This review discusses the current state of multicancer early detection tests, the role of machine learning in their development, and their implications for oncology practice and patient care.
Overcoming Challenges in Adopting Epigenetic Liquid Biopsy for Prostate Cancer
Jacob E. Berchuck, MD, highlights challenges in adopting liquid biopsy for PSMA expression and its potential to revolutionize precision medicine in prostate cancer.
Trial of ARC101 Doses First Patient With CLDN6+ Solid Tumors
ARC101, a potential best-in-class T-cell engager that targets solid tumors expressing CLDN6, is being assessed in a first-in-human trial.
Kato Breaks Down FDA Approval of Tislelizumab in Esophageal Cancer
Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma.
Sacituzumab Govitecan Shows Consistent Efficacy in Real-World mTNBC
In metastatic triple-negative breast cancer, sacituzumab govitecan was effective and tolerable in the real-world setting.
Eggener Urges Pragmatic Approach to Prostate Cancer Innovations
Scott Eggener, MD, gave a talk at the LUGPA annual meeting titled “Leveraging Cutting-Edge Technologies to Enhance Prostate Cancer Treatments.”
Experts Discuss Tislelizumab’s FDA Approval in Esophageal Cancer
Ken Kato, MD, PhD, and Harry H. Yoon, MD, MHS, discussed the recent FDA approval of tislelizumab in the first line for patients with esophageal squamous cell carcinoma.
Organ-Sparing TMLI Enhances AML Transplant Outcomes
Anthony Stein, MD, assessed total marrow and lymphoid irradiation with post-transplant cyclophosphamide in patients with acute myeloid leukemia.
Novel rhPSMA Therapy Targets Advanced Prostate Cancer With Precision
177Lu rhPSMA-10.1 showed high tumor radiation with low healthy tissue exposure in a phase 1/2 trial for metastatic castration-resistant prostate cancer.
Elacestrant Shows Superior PFS vs SOC in EMERALD Subgroup Analysis
Elacestrant prolonged progression-free survival in patients with pretreated, ER-positive, HER2-negative breast cancer.
BMT CTN 1902 in Myeloma: Key Findings With Garfall
In this episode of Targeted Talks, Alfred L. Garfall, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in patients with multiple myeloma.
Actimab-A Triplet Trial Launches in Frontline AML
A phase 1 trial is evaluating Actimab-A, venetoclax, and ASTX-727 in frontline acute myeloid leukemia, with initial data expected later this year.
HER2DX Test Transforms Treatment Decisions in HER2+ Breast Cancer
A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.
Phase 2 Trial of OSE2101 in Advanced PDAC Meets Primary End Point
The TEDOPaM trial evaluating a novel maintenance therapy approach for advanced/metastatic pancreatic ductal adenocarcinoma has met its primary end point.
EAP Enhances Access to Cretostimogene Grenadenorepvec
An expanded access program evaluating cretostimogene grenadenorepvec was highlighted during the 25th Annual Meeting of the Society of Urologic Oncology.
Expert Explores Trials in CIS-Refractory Bladder Cancer
Jason M. Hafron, MD, CMO, discusses recent approvals in the non–muscle-invasive bladder cancer space and data from several clinical trials evaluating agents for bladder cancer.
Shouse Covers the Future of Lymphoma Therapy With Bispecific Antibodies
Geoffrey Shouse, DO, PhD, discusses the growing interest in bispecific antibodies within the field of oncology.
Aging Population, Burnout Continue to Drive Oncology Workforce Shortage
Julie Gralow, MD, shed light on the factors contributing to the growing shortage of oncologists in the US and what can be done to address it.
HER2 Therapies Redefine Brain Metastasis Treatment in Breast Cancer
Novel HER2 therapies show strong intracranial efficacy, enabling systemic treatment over local therapy for small, asymptomatic brain metastases in metastatic breast cancer.
Gemcitabine-BCG Shows Early Promise in BCG-Exposed NMIBC
BCG with gemcitabine was linked to strong early oncological efficacy and safety in previously treated patients with non–muscle-invasive bladder cancer.
Advancing Treatments for ET and CDK4/6 Resistance in HR+ Breast Cancer
New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.
Breakthroughs in Lung Cancer Research and Early Detection Strategies
Jennifer Marie Suga, MD, shares the lung cancer research she’s eager to explore as new data emerges.
Odronextamab Shows Efficacy in DLBCL Post CAR T-Cell Therapy
Matthew Matasar, MD, discussed what the findings from the ELM-1 trial of odronextamab in diffuse large B-cell lymphoma mean for oncologists.
Evofosfamide Trial Targets Hypoxia in Resistant Solid Tumors
The first patient was dosed in a phase 1/2 trial of evofosfamide with checkpoint inhibitors for hypoxia-reversal in resistant solid tumors.
Cystectomy-Free Survival Is Detailed With Nadofaragene
Treatment of unresponsive non–muscle-invasive bladder cancer with nadofaragene firadenovec showed a 66% chance of survival and cystectomy-free status at 60 months.
The Targeted Pulse: New Trial Evaluating Iadademstat/Azacitidine in MDS and Positive Trends in HNSCC
Forward steps are being made in HNSCC, and the first patient with MDS has been treated with iadademstat/azacitidine.
